# An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

> **NCT01796301** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 436 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Romozosumab
- **DRUG:** Teriparatide

## Key facts

- **NCT ID:** NCT01796301
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-31
- **Primary completion:** 2015-05-14
- **Final completion:** 2015-05-14
- **Target enrollment:** 436 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796301, "An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01796301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*